FDA Approval Alert: The Need-to-Know | 177Lu-PSMA-617 for Pretreated PSMA+ Metastatic Castration-Resistant Prostate Cancer

In March 2022, the FDA granted approval to the targeted radioligand 177Lu-PSMA-617 for the treatment of patients with prostate-specific membrane antigen–positive metastatic castration-resistant prostate cancer who have previously been treated with an androgen-receptor pathway inhibitor and taxane-based chemotherapy.

Phillip S. Low, PhD, Discusses Next Steps in Research of 177Lu-PSMA-617 for mCRPC and Other Cancers
Phillip S. Low, PhD, Discusses Next Steps in Research of 177Lu-PSMA-617 for mCRPC and Other Cancers
Video
Apr 14, 2022 8:00 PM
Phillip S. Low, PhD, spoke about what the future holds for treatments like 177Lu-PSMA-617 being developed for patients with prostate cancer.
Phillip S. Low, PhD, Provides In-Depth View of 177Lu-PSMA-617 Development for Metastatic CRPC
Phillip S. Low, PhD, Provides In-Depth View of 177Lu-PSMA-617 Development for Metastatic CRPC
Article
Mar 31, 2022 6:00 PM
Phillip S. Low, PhD, pioneered development of 177Lu-PSMA-617 for patients with metastatic castration-resistant prostate cancer and spoke about its recent approval.
FDA Approves 177Lu-PSMA-617 for Pretreated PSMA+ Metastatic Castration-Resistant Prostate Cancer
FDA Approves 177Lu-PSMA-617 for Pretreated PSMA+ Metastatic Castration-Resistant Prostate Cancer
Article
Mar 23, 2022 9:11 PM
Based on data from the phase 3 VISION trial, 177Lu-PSMA-617 may now be used to treat patients who were previously treated with androgen receptor pathway inhibitors plus taxane-based chemotherapy for metastatic prostate specific membrane antigen–positive castration-resistant prostate cancer.